Olimab 60mg injection
Rx RequiredSalt Composition: Denosumab
Expiry Date: 01/2028
Price on Request
Inclusive of all taxes
1 Prefilled Syringe(s) Of 1ml
About The Product
Bone disease
Olimab 60mg Injection contains Denosumab as an active ingredient that is a monoclonal antibody. Doctor prescribes it to treat osteoporosis in postmenopausal women and in men at increased risk of fractures. It makes the bones strong as well as reduces the risk of fractures.
It works by binding to a protein that causes bone loss, thereby strengthening the bone and minimizing the risk of fractures. It should be given by healthcare professional only do not self administer this injection.
Uses
Osteoporosis
Side Effects
Every medicine has some side effects that manage on their own as your body gets used to the medicine, but some people may rarely experience severe side effects. In that case, the patient should contact the doctor immediately.
Some common side effects of Olimab 60mg Injection include:
- Rash
- Musculoskeletal (bone, muscle or joint) pain
- Eczema
- Upper respiratory tract infection
- Sciatica
- Pain in extremities
- Back pain
- Joint pain
- Urinary tract infection
- Constipation
- Abdominal discomfort
- Hair loss
- Hypercholesterolemia (high cholesterol)
- Cystitis
- Nerve pain
- Headache
How To Use
Olimab 60mg Injection is a powerful monoclonal antibody. that can only be given by a doctor or nurse under strict medical supervision.
It is not self-administerable. Dosage and duration of the treatment are determined by the doctor as per the patient's health condition and type of the disease.
How It Works
Olimab 60mg Injection contains Denosumab as an active ingredient that is a monoclonal antibody. It makes the bones strong as well as reduces the risk of fractures.
It works by binding to a protein that causes bone loss, thereby strengthening the bone and minimizing the risk of fractures.
Safety Advice
FAQs
There are some common yet manageable side effects of taking Olimab Injection that include pain in extremities, back pain, joint pain, urinary tract infection, constipation, etc.
References
- Burkiewicz, J. S., Scarpace, S. L., & Bruce, S. P. (2009). Denosumab in osteoporosis and oncology. Annals of Pharmacotherapy, 43(9), 1445-1455.
- Miyazaki, T., Tokimura, F., & Tanaka, S. (2014). A review of denosumab for the treatment of osteoporosis. Patient preference and adherence, 463-471.
- Cummings, S. R., Martin, J. S., McClung, M. R., Siris, E. S., Eastell, R., Reid, I. R., ... & Christiansen, C. (2009). Denosumab for prevention of fractures in postmenopausal women with osteoporosis. New England Journal of Medicine, 361(8), 756-765.
- Deeks, E. D. (2018). Denosumab: a review in postmenopausal osteoporosis. Drugs & aging, 35(2), 163-173.
- Kendler, D. L., Cosman, F., Stad, R. K., & Ferrari, S. (2022). Denosumab in the treatment of osteoporosis: 10 years later: a narrative review. Advances in therapy, 39(1), 58-74.
- Zaheer, S., LeBoff, M., & Lewiecki, E. M. (2015). Denosumab for the treatment of osteoporosis. Expert opinion on drug metabolism & toxicology, 11(3), 461-470.
Medical Disclaimer
Accurate, reviewed information to support informed healthcare decisions
Magicine's primary objective is to ensure that its customers receive accurate, genuine, and trustworthy information reviewed by medical experts.
The content on this website has been produced solely for informational purposes. This is not intended to take the place of medical advice and care provided by a licensed professional, though.
This information may not include all potential side effects, warnings, and details about specific lab tests, medications, and medical conditions. Please ask your doctor any questions you may have about any drug or disease.
Our goal is not to replace or substitute for the doctor-patient relationship, but to uphold and strengthen it.
.png&w=48&q=75 "Cart"){kind=small}
9655.png&w=48&q=75 "Home"){kind=small}
